James Johnson
Direktor/Vorstandsmitglied bei ATHIRA PHARMA, INC.
Vermögen: 13 100 $ am 31.05.2024
Aktive Positionen von James Johnson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ATHIRA PHARMA, INC. | Direktor/Vorstandsmitglied | 01.08.2020 | - |
Independent Dir/Board Member | 01.08.2020 | - |
Karriereverlauf von James Johnson
Ehemalige bekannte Positionen von James Johnson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Nohla Therapeutics, Inc.
Nohla Therapeutics, Inc. BiotechnologyHealth Technology Nohla Therapeutics, Inc. developed cellular therapies for hematological disorders. The firm's products used without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. The company was founded by Colleen Delaney and was headquartered in Seattle, WA. | Finanzdirektor/CFO | 01.01.2018 | 01.08.2019 |
NS WIND DOWN CO., INC. | Comptroller/Controller/Auditor | 03.10.2012 | 31.12.2017 |
Finanzdirektor/CFO | 03.10.2012 | 31.12.2017 | |
RELYPSA INC | Finanzdirektor/CFO | 01.05.2011 | 01.09.2012 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Finanzdirektor/CFO | 01.02.2001 | 01.10.2010 |
Unternehmenssekretär | 28.05.2010 | 01.10.2010 | |
Treasurer | 01.02.2001 | 01.10.2010 | |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Verwaltungsdirektor | 01.01.1999 | 01.02.2001 |
Finanzdirektor/CFO | 01.01.1994 | 01.02.2001 | |
Unternehmenssekretär | 01.01.1994 | 01.02.2001 | |
Treasurer | 01.01.1994 | 01.02.2001 | |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Finanzdirektor/CFO | 01.01.1988 | 01.01.1994 |
C3J Therapeutics, Inc.
C3J Therapeutics, Inc. BiotechnologyHealth Technology C3J Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of novel targeted antimicrobials-synthetic bacteriophage and antimicrobial peptides. The company was founded by Randal Eckert, Maxwell H. Anderson and Wenyuan Shi in 2005 and is headquartered in Marina del Rey, CA. | Finanzdirektor/CFO | - | - |
Ausbildung von James Johnson
University of Washington | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Director of Finance/CFO | 7 |
Corporate Secretary | 2 |
Treasurer | 2 |
Sektoral
Health Technology | 9 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
NS WIND DOWN CO., INC. | Health Technology |
ATHIRA PHARMA, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Nohla Therapeutics, Inc.
Nohla Therapeutics, Inc. BiotechnologyHealth Technology Nohla Therapeutics, Inc. developed cellular therapies for hematological disorders. The firm's products used without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. The company was founded by Colleen Delaney and was headquartered in Seattle, WA. | Health Technology |
C3J Therapeutics, Inc.
C3J Therapeutics, Inc. BiotechnologyHealth Technology C3J Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of novel targeted antimicrobials-synthetic bacteriophage and antimicrobial peptides. The company was founded by Randal Eckert, Maxwell H. Anderson and Wenyuan Shi in 2005 and is headquartered in Marina del Rey, CA. | Health Technology |
- Börse
- Insiders
- James Johnson
- Erfahrung